ProfileGDS5678 / 1454718_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 82% 80% 80% 81% 82% 82% 78% 81% 80% 81% 80% 81% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7455981
GSM967853U87-EV human glioblastoma xenograft - Control 26.0279982
GSM967854U87-EV human glioblastoma xenograft - Control 35.6559580
GSM967855U87-EV human glioblastoma xenograft - Control 45.7382980
GSM967856U87-EV human glioblastoma xenograft - Control 55.8391581
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7471882
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7853382
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4194578
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7354481
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7346180
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7364381
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7386480
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7457281
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7398481